Adma Biologics Inc [ADMA] stock is trading at $19.54, up 0.26%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ADMA shares have gain 3.77% over the last week, with a monthly amount glided 6.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Buy rating on October 13, 2022, and set its price target to $5. On November 11, 2021, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $5 on the stock. Cantor Fitzgerald started tracking the stock assigning an Overweight rating and suggested a price target of $4.50 on November 09, 2021. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on June 04, 2019. H.C. Wainwright reiterated a Buy rating for this stock on April 15, 2019, and upped its price target to $13.
Adma Biologics Inc [ADMA] stock has fluctuated between $13.50 and $25.67 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Adma Biologics Inc [NASDAQ: ADMA] shares were valued at $19.54 at the most recent close of the market. An investor can expect a potential drop of -18.12% based on the average ADMA price forecast.
Analyzing the ADMA fundamentals
Adma Biologics Inc [NASDAQ:ADMA] reported sales of 488.56M for the trailing twelve months, which represents a growth of 12.00%. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.44%. To continue investigating profitability, this company’s Return on Assets is posted at 0.37, Equity is 0.62 and Total Capital is 0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.37 points at the first support level, and at 19.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.70, and for the 2nd resistance point, it is at 19.86.
Ratios To Look Out For
For context, Adma Biologics Inc’s Current Ratio is 7.13. In addition, the Quick Ratio stands at 3.65 and the Cash Ratio stands at 1.2. Considering the valuation of this stock, the price to sales ratio is 9.52, the price to book ratio is 10.80 and price to earnings (TTM) ratio is 22.95.
Transactions by insiders
Recent insider trading involved Grossman Adam S, President and CEO, that happened on Dec 15 ’25 when 21000.0 shares were sold. President and CEO, Grossman Adam S completed a deal on Nov 19 ’25 to sell 21000.0 shares. Meanwhile, President and CEO Grossman Adam S sold 21000.0 shares on Oct 24 ’25.
